Molecular Markers in Native American Women With Breast Cancer
18 Years
N/A
Female
Breast Cancer
Trial Information
Molecular Markers in Native American Women With Breast Cancer
OBJECTIVES:
- Evaluate a selected panel of molecular markers in tissue specimens from Native American
women with breast cancer.
- Determine which molecular markers provide independent prognostic information with
respect to traditional prognostic factors in these patients.
- Compare and contrast the prevalence of positivity in Native American women with breast
cancer with an age- and stage-matched cohort of Caucasian women with breast cancer
enrolled on clinical trial NCCTG-77-30-51 or the Mayo Breast Cancer Registry.
OUTLINE: Immunohistochemistry is performed on tumor samples to analyze the following
molecular markers: estrogen receptor, progesterone receptor, c-erbB2, p53, Ki-67, Bcl-2,
Bax, cyclin D-1, and insulin-like growth factor-1R.
PROJECTED ACCRUAL: A total of 300 tissue samples (150 from Native American women and 150
from Caucasian women) will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of primary adenocarcinoma of the breast in Native American women
- Prior surgical treatment for breast cancer within the Aberdeen or Phoenix areas of
the Indian Health Service or the Alaska area of the Native Health Service between
1990-2000
- Paraffin-embedded tissue available
- Paraffin-embedded tissue available from Caucasian women with breast cancer enrolled
on NCCTG-77-30-51 or the Mayo Breast Cancer Registry
- Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Female
Menopausal status
- Not specified
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Evaluation of a selected panel of molecular markers in tissue specimens from Native American women with breast cancer
Safety Issue:
No
Principal Investigator
Judith S. Kaur, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Mayo Clinic
Authority:
United States: Federal Government
Study ID:
CDR0000078596
NCT ID:
NCT00898976
Start Date:
August 1998
Completion Date:
Related Keywords:
- Breast Cancer
- stage I breast cancer
- stage II breast cancer
- stage IV breast cancer
- stage IIIA breast cancer
- breast cancer in situ
- recurrent breast cancer
- stage IIIB breast cancer
- inflammatory breast cancer
- stage IIIC breast cancer
- Breast Neoplasms
Name | Location |
|---|
